Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010003022 - ISOINDOLONE DERIVATIVES AS MEK KINASE INHIBITORS AND METHODS OF USE

Publication Number WO/2010/003022
Publication Date 07.01.2010
International Application No. PCT/US2009/049449
International Filing Date 01.07.2009
IPC
C07D 209/44 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02condensed with one carbocyclic ring
44Iso-indoles; Hydrogenated iso-indoles
A61K 31/4035 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
4035Isoindoles, e.g. phthalimide
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 29/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
CPC
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
C07D 209/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02condensed with one carbocyclic ring
44Iso-indoles; Hydrogenated iso-indoles
46with an oxygen atom in position 1
Applicants
  • GENENTECH, INC. [US]/[US] (AllExceptUS)
  • GANCIA, Emanuela [IT]/[GB] (UsOnly)
  • HEALD, Robert, Andrew [GB]/[GB] (UsOnly)
  • JACKSON, Philip [GB]/[GB] (UsOnly)
  • PRICE, Stephen [GB]/[GB] (UsOnly)
Inventors
  • GANCIA, Emanuela
  • HEALD, Robert, Andrew
  • JACKSON, Philip
  • PRICE, Stephen
Agents
  • BUCKWALTER, Brian, L.
Priority Data
61/077,43201.07.2008US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ISOINDOLONE DERIVATIVES AS MEK KINASE INHIBITORS AND METHODS OF USE
(FR) DÉRIVÉS D'ISOINDOLONE UTILISÉS EN TANT QU'INHIBITEURS DE KINASE MEK ET PROCÉDÉS D'UTILISATION CORRESPONDANTS
Abstract
(EN)
The invention relates to isoindoloncs of formula, (I) with anti-cancer and/or anti- inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
(FR)
La présente invention concerne des isoindolones de formule (I) ayant une activité anticancéreuse ou anti-inflammatoire et plus spécifiquement une activité d'inhibition de la MEK kinase. L'invention concerne des compositions et des procédés utiles pour l'inhibition d'une croissance cellulaire anormale, le traitement d'un trouble d'hyperprolifération, ou le traitement d'une maladie inflammatoire chez un mammifère. L'invention concerne également des procédés d'utilisation des composés pour le diagnostic ou le traitement in vitro, in situ et in vivo de cellules mammifères, ou de conditions pathologiques associées.
Latest bibliographic data on file with the International Bureau